Objective:

To evaluate the safety and efficacy of ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy.

Approach:

• Study Design: Phase II IMPROVE-HCM trial with 67 previously treated patients randomly assigned to receive either ninerafaxstat or placebo.
• Follow-Up: Patients were followed for 12 weeks to assess adverse events and clinical outcomes.

Key Findings:

• No statistically significant differences in adverse events between ninerafaxstat and placebo groups.
• Ninerafaxstat group experienced no adverse events related to low ejection fraction, blood pressure, or heart rate.
• Reductions in left atrium size and improvements in disease symptoms, including fatigue and chest discomfort, were observed.
• Kansas City Cardiomyopathy Questionnaire scores increased by nine points in the ninerafaxstat group compared to placebo.

Interpretation:

Limitations:

• Small sample size of 67 patients.
• Need for a larger phase III trial to confirm efficacy.

Conclusion:

Sources:

• Journal of the American College of Cardiology